The amendment to the Marriage Laws Bill needs to be redrafted to ensure, among other things, greater economic rights for divorced women. SINCE the 1950s, successive amendments to different personal laws on marriage and divorce have mainly focussed on enlarging the grounds for divorce. In the 1960s and 1970s, cruelty and desertion and thereafter mutual consent were added as grounds for divorce in the Hindu Marriage Act (HMA) and the...

The proposed liberalisation of the mining and minerals sector is an assault on the rightful owners of the land and its resources. Tribal and indigenous communities across the world have been asserting their rights to the mineral wealth often found under the land they own or possess or have traditional rights to. They have been historically denied even a share of that huge wealth, leave alone legal rights of ownership. Under...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

With the elderly likely to constitute a quarter of India's population by 2050, there is need for a publicly-funded, universal scheme that will overcome destitution among the aged India's social security system is woefully inadequate, when compared even to those in third world economies with no higher per capita incomes. Some States in India have fairly comprehensive social security schemes — notably Kerala, also West Bengal and Tamil Nadu — but...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...